GlobeNewsWire
06 Jul 2026, 10:50 UTC · 11w ago
Verdict
Headline takes no side. We score PHVS +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has accepted Pharvaris' New Drug Application (NDA) for deucrictibant immediate-release (IR) for the on-demand treatment of Hereditary Angioedema (HAE) attacks.
More positive than 92% of claims this week
The pivotal Phase 3 RAPIDe-3 study met its primary and all 11 secondary efficacy endpoints with statistical significance.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 76% of claims this week
The FDA has set a PDUFA target action date of April 23, 2027, for the deucrictibant IR application.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The FDA has accepted the company's New Drug Application for deucrictibant IR, marking a major milestone toward potential commercialization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+6.4%
Price agrees with the score
$36.02 vs $33.86 close before publication (Jul 2) · not market-adjusted
PHVS chart →
